FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

Upstream Bio, Inc. (NASDAQ:UPB) – Research analysts at HC Wainwright decreased their FY2028 earnings per share estimates for shares of Upstream Bio in a research report issued on Wednesday, September 2nd. HC Wainwright analyst M. Caufield now expects that the company will earn ($3.17) per share for the year, down from their previous estimate of ($3.13). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Upstream Bio’s current full-year earnings is ($2.86) per share. HC Wainwright also issued estimates for Upstream Bio’s FY2029 earnings at ($3.64) EPS and FY2030 earnings at ($3.70) EPS.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The business had revenue of $0.77 million during the quarter, compared to analysts’ expectations of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%.

A number of other brokerages have also commented on UPB. Mizuho dropped their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Weiss Ratings raised shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Wall Street Zen cut Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Truist Financial dropped their price target on Upstream Bio to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Finally, JPMorgan Chase & Co. boosted their price target on Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $29.67.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $6.08 on Friday. Upstream Bio has a 1 year low of $5.77 and a 1 year high of $33.68. The business has a 50-day moving average of $6.96 and a two-hundred day moving average of $7.91. The company has a market capitalization of $333.00 million, a P/E ratio of -2.10 and a beta of 1.28.

Institutional Investors Weigh In On Upstream Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its stake in shares of Upstream Bio by 6.4% during the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock worth $179,000 after buying an additional 985 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Upstream Bio by 8.4% during the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock worth $181,000 after acquiring an additional 1,275 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after buying an additional 1,440 shares in the last quarter. Empowered Funds LLC acquired a new position in Upstream Bio during the fourth quarter worth $45,000. Finally, BNP Paribas Financial Markets increased its holdings in Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after buying an additional 2,158 shares during the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.